NCT05415761 Comparative Effectiveness of Mobile Health Smoking Cessation Approaches Among Underserved Patients in Primary Care
| NCT ID | NCT05415761 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Florida |
| Condition | Tobacco Use Cessation |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,332 participants |
| Start Date | 2023-05-15 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,332 participants in total. It began in 2023-05-15 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will evaluate the comparative effectiveness of three smoking cessation therapies: mobile health (mHealth) application iCanQuit, mHealth application iCanQuit + Motiv8, and the Florida quit line.
Eligibility Criteria
Inclusion Criteria: * ≥21 years old * Referred by the provider via Ask-Advise-Connect * Receiving care at one of the participating clinics * Daily access to their own smart phone (the study team will provide assistance to patients without a phone to obtain one through aid programs for low-income patients) * No household members already enrolled Exclusion Criteria: * Unstable medical or psychiatric illness
Contact & Investigator
Jesse Dallery, PhD
PRINCIPAL INVESTIGATOR
University of Florida
Frequently Asked Questions
Who can join the NCT05415761 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, studying Tobacco Use Cessation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05415761 currently recruiting?
Yes, NCT05415761 is actively recruiting participants. Contact the research team at dallery@ufl.edu for enrollment information.
Where is the NCT05415761 trial being conducted?
This trial is being conducted at Gainesville, United States.
Who is sponsoring the NCT05415761 clinical trial?
NCT05415761 is sponsored by University of Florida. The principal investigator is Jesse Dallery, PhD at University of Florida. The trial plans to enroll 1,332 participants.